An Early Clinical Trial to Evaluate VGN-R09b for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Clinical Trial

Official title:

An Open, Dose-escalating Early Clinical Trial to Evaluate the Tolerability, Safety, and Efficacy of VGN-R09b by Intra Striatum Injection in Patients With Aromatic L-amino Acid Decarboxylase (AADC) Deficiency.

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05765981
• Other study ID #: VGN-R09b-001
• Status: Recruiting
• Phase: Early Phase 1
• Start date: January 30, 2023
• Est. completion date: February 20, 2029

Study information

• Verified date: March 2023
• Source: Shanghai Jiao Tong University School of Medicine
• Contact: Jiwen Wang, Doctor
• Phone: 18916613192
• Email: wangjiwen[@]scmc.com.cn
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This early Phase trial is to prove the safety and efficacy of VGN-R09b to treat patients with AADC deficiency.

Description:

Aromatic L-amino acid decarboxylase (AADC) is an enzyme responsible for the final step in the synthesis of neurotransmitters dopamine and serotonin. AADC deficiency is a rare genetic disorder. VGN-R09b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human AADC (hAADC) being injected directly into striatum.

This is a single-center, open, dose-climbing investigator-sponsored early-stage clinical study that included a dose-climbing phase and a dose-expanding phase.

This study is to give preliminary evidence for the safety and efficacy of VGN-R09b treatment for patients with Aromatic L-amino acid decarboxylase (AADC) deficiency.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 6
• Est. completion date: February 20, 2029
• Est. primary completion date: February 20, 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 24 Months to 7 Years

Eligibility

Inclusion Criteria:

1. The child patient has to be =2 years old and < 8 years old, or a head circumference big enough for surgery.

2. Historical diagnosis of AADC deficiency with clinical symptoms consistency, AND confirmed by one of the lab tests: (1) CSF neurotransmitter profile demonstrating reduced HVA and 5-HIAA, and elevated L-Dopa concentrations; (2) Plasma AADC activity less than or equal to 5 pmol/min/mL, AND with Molecular genetic confirmation of homozygous or compound heterozygous mutation of IVS6+4A>T in DDC.

3. Motor development at baseline =3 months, and Failed to benefit from standard medical therapy (dopamine agonists, monoamine oxidase inhibitor or related form of Vitamin B6) at discretion of investigators.

4. Stable medication regimen for treatment of AADC deficiency: (i.e. no new medications introduced for at least 6 months, and no existing medication dose changes for at least 3 months prior to Baseline).

5. Parent(s)/legal guardian(s) with custody of subject must give their consent for subject to enroll in the study

6. Parent(s)/legal guardian(s) of the subject must agree to comply with the requirements of the study, including providing disease information and support disease assessment of symptoms.

Exclusion Criteria:

1. Intracranial neoplasm or any structural brain abnormality or lesion (e.g., severe brain atrophy, white matter degenerative changes), which, in the opinion of the study investigators, would confer excessive risk and/or inadequate potential for benefit.

2. Presence of other significant medical or neurological conditions that would create an unacceptable operative or anesthetic risk (including congenital heart disease, respiratory disease with home oxygen requirement, history of serious anesthesia complications during previous elective procedures, history of cardiorespiratory arrest), liver or renal failure, malignancy, or HIV positive.

3. Severe coagulopathy, or need for ongoing anticoagulant therapy.

4. clinically active infection or with severe infection within 12 weeks before screening (e.g. adenovirus or herpes virus, pneumonia, sepsis, central nervous system infection).

5. Previous stereotactic neurosurgery, or any gene/cell therapy.

6. Received live vaccination within 4 weeks.

7. Patients with anti-AAV9 neutralizing antibody titer over 1,200 folds.

8. Contraindication to sedation during surgery or imaging studies (PET or MRI).

Related Conditions & MeSH terms

• Aromatic L-amino Acid Decarboxylase (AADC) Deficiency

Intervention

Drug:
• VGN-R09b
VGN-R09b will be injected into bilateral putamen by stereotactic surgery.(Through the SmartFlow Ventricular Cannula or the parenchymal injection tube actually used in the research center)

Locations

Country	Name	City	State
China	Shanghai Children's Medical Center Affiliated to Shanghai Jiao Tong University School of Medicine	Shanghai	No. 1678, Dongfang Road, Pudong New Area, Shanghai

Sponsors (2)

Lead Sponsor	Collaborator
Shanghai Jiao Tong University School of Medicine	Shanghai Vitalgen BioPharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events (AEs), Serious Adverse Events (SAEs)	Number of Adverse Events (AEs), Serious Adverse Events (SAEs)	Week 52
Primary	Achievement Ratio of the four motor development milestones (Head control, Sit independently, Stand/stepping with support and Walk with minimal assistant)	Achievement Ratio of the four motor development milestones (Head control, Sit independently, Stand/stepping with support and Walk with minimal assistant) according to PDMS-II score.	Week 52